Dunhill Financial’s Bio-Rad Laboratories Class A BIO Stock Holding History

Dunhill Financial’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$555	Hold	1	–	–	﹤0.01%	1116
2026 Q1	$495	Hold	1	–	–	﹤0.01%	1102
2025 Q4	$339	Hold	1	–	–	﹤0.01%	993
2025 Q3	$145	Hold	1	–	–	﹤0.01%	946
2025 Q2	$207	Sell	1 -4	-80%	-$946	﹤0.01%	942
2025 Q1	$1.3K	Sell	5 -1	-17%	-$301	﹤0.01%	790
2024 Q4	$2.01K	Buy	6 +1	+20%	+$339	﹤0.01%	708
2024 Q3	$1.58K	Buy	5 +2	+67%	+$635	﹤0.01%	749
2024 Q2	$703	Buy	3 +1	+50%	+$291	﹤0.01%	732
2024 Q1	$750	Hold	2	–	–	﹤0.01%	679
2023 Q4	$593	Buy	+2	New	+$627	﹤0.01%	682

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Dunhill Financial's BIO Position: Q2 2026 in Review

Dunhill Financial held its Bio-Rad Laboratories Class A (BIO) position steady in Q2 2026 at 1 share worth $555. The position accounts for ﹤0.01% of the portfolio, ranked #1116.

Dunhill Financial first reported a position in BIO in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.01K in Q4 2024. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

Dunhill Financial held 1 share of Bio-Rad Laboratories Class A worth $555 as of Q2 2026.
Dunhill Financial left its Bio-Rad Laboratories Class A share count unchanged in Q2 2026.
Bio-Rad Laboratories Class A made up ﹤0.01% of Dunhill Financial's portfolio in Q2 2026, its #1116 holding.
Dunhill Financial first reported a position in Bio-Rad Laboratories Class A in Q4 2023 and has held it in 11 quarters since.
Dunhill Financial's Bio-Rad Laboratories Class A position peaked at $2.01K in Q4 2024.
398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Dunhill Financial's 13F filing for Q2 2026, filed 7 Aug 2026.